The pharmaceutical company company Eurofarma announced on the night of Thursday (21) a net loss of R $ 92.6 million In the second quarter, less than the loss of R $ 205.2 million calculated in the same stage as last year, with operational improvement effect in the period.
EBITDA (profit before interest, taxes, depreciation and amortization) jumped to R $ 301.4 million in the second quarter, from R $ 72.5 million a year earlier. With adjustments, EBITDA expanded 89%to R $ 476.6 million, according to results report.
Net revenue reached R $ 2.7 billion, 15.3% over a year earlier, with the growth of prescription, generic units and highlighting the launch of products. In Brazil, sales reached R $ 1.9 billion, up 18.8% year to year, representing 72% of total sale. Eurofarma has a presence in 24 countries.
The company, which has market share 3.8% in the pharmacy segment, 4.5% in prescription and 10.4% in generics, concluded in May the acquisition of 60% of the dermage dermocosmetics brand, and in June concluded the operation that resulted in the formation of a joint venture with South Korean SK Biophamaceticals.
